Skip to main content
Livermore
Livermore
ZHEN

Wildcat Capital Management, LLC

SEC CIK
0001582384
Latest filing
Jul 22, 2026

The latest 13F from Wildcat Capital Management, LLC covers Q2 2026 (filed Jul 22, 2026): 3 long positions worth $228.5M. The top 10 holdings make up 100.0% of the portfolio, and the largest is Frontier Group Holdings, Inc. (ULCC) at 97.1%. Livermore has 24 filings on Form 13F from this institution, going back to Q1 2021.

What changed in Q2 2026

Share counts compared with Q1 2026: how many positions were new, added to, reduced or sold out, and the biggest buys and sells. Dollar amounts are estimated at the quarter-end prices implied by the filing.

Full comparison
New
1
Est. +$488.9K
Added
0
Reduced
0
Sold out
0

Top 5 holdings

Share of this quarter's portfolio value

  1. ULCCFrontier Group Holdings, Inc.
    97.1%$222.0MHistory
  2. ALLOAllogene Therapeutics, Inc.
    2.7%$6.08MHistory
  3. CHYMChime Financial, Inc.
    0.2%$488.9KHistory

Share of portfolio

Each position's share of portfolio value

  1. ULCC97.1%
  2. ALLO2.7%
  3. CHYM0.2%

Biggest buys

New and added positions, by estimated amount bought

  1. CHYMChime Financial, Inc.
    +$488.9KNewHistory

Largest weight increases

New and added positions, by percentage points of the portfolio gained

  1. CHYMChime Financial, Inc.
    +0.21 pp0.0% → 0.2%History

Biggest sells

Reduced and sold-out positions, by estimated amount sold

None this quarter.

Largest weight decreases

Reduced and sold-out positions, by percentage points of the portfolio lost

None this quarter.

Metrics

13F metrics for Q2 2026, computed only from the numbers in the filings. Definitions below.

Portfolio value
$228.5M
+$122.3M (+115.2%) vs. prior quarter
Positions
3
+1 vs. prior quarter
Top 10 concentration
100.0%
Top 10 as share of value
Turnover
0.0%
Q2 2026, one quarter
Average holding period
9.3 quarters
Weighted by value

How these are calculated

  • Portfolio value: the market value of all long positions in the 13F, as reported at quarter end, excluding options.
  • Top 10 concentration: the combined value of the 10 largest positions as a share of portfolio value.
  • Turnover: the smaller of this quarter's estimated purchases and estimated sales, divided by the average of this and last quarter's portfolio value. Estimates multiply the change in shares by the quarter-end price implied by the filing (market value divided by shares); new positions use this quarter's value and sold-out positions last quarter's. Only positions reported in shares count, and it is not calculated when the previous quarter was not filed.
  • Average holding period: how many consecutive quarters each current position has been held (including this one; a quarter without the position or without a filing starts the count over), weighted by this quarter's value. Counting starts with the first 13F in Livermore (Q1 2021), so positions held before then are understated.

13F filings by quarter

22 quarters, going back to Q1 2021. Bars show each quarter's 13F portfolio value; quarters without a filing are left blank.

Peak $881.3M (Q2 2021)

Q1 2021: $818.0MQ2 2021: $881.3MQ3 2021: $772.3MQ4 2021: $614.1MQ1 2022: $390.8MQ2 2022: $301.9MQ3 2022: $260.2MQ4 2022: $261.9MQ1 2023: $269.1MQ2 2023: $262.8MQ3 2023: $249.0MQ4 2023: $289.2MQ1 2024: $275.5MQ2 2024: $408.6MQ3 2024: $204.6MQ4 2024: $252.7MQ1 2025: $187.4MQ2 2025: $168.3MQ3 2025: $145.1MQ4 2025: $136.5MQ1 2026: $106.2MQ2 2026: $228.5M
Q1 2021Q2 2026
13F filings of Wildcat Capital Management, LLC by quarter
QuarterFiledPositionsValueTop 3 holdingsChangesFiling
Q2 2026Jul 22, 20263$228.5MULCCALLOCHYMvs. Q1 2026SEC
Q1 2026May 1, 20262$106.2MULCCALLOvs. Q4 2025SEC
Q4 2025Feb 3, 20263$136.5MULCCALLOPCORvs. Q3 2025SEC
Q3 2025Nov 14, 20255$145.1MULCCRLXALLOvs. Q2 2025SEC
Q2 2025Jul 18, 20256$168.3MULCCRLXTICvs. Q1 2025SEC
Q1 2025May 2, 20258$187.4MULCCRLXTICvs. Q4 2024SEC
Q4 2024Jan 29, 20258$252.7MULCCRLXALLOvs. Q3 2024SEC
Q3 2024Nov 8, 20247$204.6MULCCRLXALLOvs. Q2 2024SEC
Q2 2024Aug 14, 202416$408.6MULCCFYBRMCOvs. Q1 2024SEC
Q1 2024May 14, 202416$275.5MGSHDFYBRMCOvs. Q4 2023SEC
Q4 2023Feb 13, 202420$289.2MGSHDRLXFYBRvs. Q3 2023SEC
Q3 2023Nov 9, 202320$249.0MGSHDGLBERLXvs. Q2 2023SEC
Q2 2023Aug 11, 202317$262.8MGSHDRLXGLBEvs. Q1 2023SEC
Q1 2023Aug 10, 2023Amended23$269.1MRLXGSHDMETAvs. Q4 2022SECSEC
Q4 2022Feb 7, 202328$261.9MRLXTDGCPNGvs. Q3 2022SEC
Q3 2022Nov 8, 202230$260.2MRLXCSGPALLOvs. Q2 2022SEC
Q2 2022Nov 8, 2022Amended27$301.9MRLXFIRYCSGPvs. Q1 2022SEC
Q1 2022May 13, 202225$390.8MFIRYRLXCSGPvs. Q4 2021SEC
Q4 2021Feb 14, 202224$614.1MFIRYRLXGSHDvs. Q3 2021SEC
Q3 2021Nov 15, 202125$772.3MFIRYRLXGSHDvs. Q2 2021SEC
Q2 2021Aug 16, 202121$881.3MFIRYCSGPGSHDvs. Q1 2021SEC
Q1 2021May 17, 202123$818.0MFIRYCSGPALLO–SEC

13D and 13G filings

Companies where Wildcat Capital Management, LLC reports owning 5% or more on Schedule 13D or 13G, and its latest filings.

Current stakes of 5% or more

1 company, largest stake first.

Companies where Wildcat Capital Management, LLC owns 5% or more
CompanyLatest formStakeChangeFirst filedLatest filingFiling
VICPVicapsys Life Sciences, Inc.13G18.80%6.07M sharesNewMar 21, 20251 filingMar 21, 2025SEC

Latest filings

10 filings on file made by Wildcat Capital Management, LLC or listing it as a reporting person, newest first.

Schedule 13D and 13G filings by Wildcat Capital Management, LLC
CompanyFiled (ET)FormStakeChangeEvent dateFiling
SLXNSilexion Therapeutics CorpJun 26, 20254:15 PM ET13D/A1.30%113.4K shares–Below 5%Jun 26, 2025SEC
VICPVicapsys Life Sciences, Inc.Mar 21, 20256:33 PM ET13G18.80%6.07M sharesNewApr 20, 2020SEC
FIRYFiry Inc.Dec 12, 202413D/AOld format–––SEC
SLXNSilexion Therapeutics CorpAug 22, 202413DOld format–New–SEC
ULCCFrontier Group Holdings, Inc.Apr 8, 202413GOld format–New–SEC
FIRYFiry Inc.Jan 5, 202313D/AOld format–––SEC
URGNUroGen Pharma Ltd.Feb 14, 202213G/AOld format–––SEC
FIRYFiry Inc.Mar 23, 202113D/AOld format–––SEC
FIRYFiry Inc.Mar 8, 202113D/AOld format–––SEC
URGNUroGen Pharma Ltd.Feb 12, 202113G/AOld format–––SEC